Industry Voices 5g and the Potential for Widespread Healthcare Disruption

Fiercehealthcare | May 15, 2019

Historically, the healthcare industry has been slower to adopt new and emerging technologies partially due to regulatory boundaries and legacy IT infrastructure. But as of late, the healthcare industry is rapidly becoming one of the most technologically advanced in the world. New and emerging technologies are becoming established tools that help healthcare companies and professionals provide exceptional customer service and patient care. This is also spurring new startups that are entering the fray with innovative ideas to disrupt this industry with data, analytics, robotics, automation, and artificial intelligence. The range of benefits includes the complete value chain of healthcare, everything from administrative duties, such as triage and payments, to medical diagnostics, advanced medicine, clinical trials and collaborative initiatives at life sciences organizations.

Spotlight

We're a passionate team dedicated to health and fitness who are building products that help transform people's lives. While health can be serious business, we feel it doesn't have to be. We believe you're more likely to reach your goals if you're encouraged to have fun, smile, and feel empowered along the way.

Spotlight

We're a passionate team dedicated to health and fitness who are building products that help transform people's lives. While health can be serious business, we feel it doesn't have to be. We believe you're more likely to reach your goals if you're encouraged to have fun, smile, and feel empowered along the way.

Related News

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

HEALTH TECHNOLOGY

Conformis Announces New Agreement with Vizient for Personalized Orthopedic Implants

Conformis, Inc. | August 02, 2022

Conformis, Inc. a leading medical device company that features personalized knee and hip replacement products, announced it has entered into a multi-year agreement with Vizient, Inc., the nation's largest member-driven health care performance improvement company. “We are excited to offer personalized orthopedic implants to Vizient’s large membership of healthcare facilities through this contract. As more orthopedic patients and surgeons seek personalized solutions, increased awareness and ease of access to our product portfolio is more important than ever. The Vizient agreement connects us to a significant number of providers, many of which have limited access and awareness of our products and our new Platinum Services Program,” Mark Augusti, Chief Executive Officer and President of Conformis The agreement gives increased access to the entire Conformis knee and hip portfolio to Vizient’s membership base, which is comprised of academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers, and includes Identity Imprint™, a personalized knee replacement system; Image-to-Implant® Platinum Services Program, a patient-elected deluxe upgrade option to obtain a fully personalized knee replacement implant; and, Cordera™ Match Hip System, a personalized primary hip replacement solution. Conformis implants improve efficiency and reduce overall costs for medical facilities. Researchers at the University of Washington in Seattle found that fully personalized total knee arthroplasty is cost-effective in comparison to a standard, off-the-shelf implant. Ongoing research suggests that fully personalized implants further reduce total costs to the healthcare system because patients recover more quickly and are less likely to require follow-up corrective surgeries. About Conformis, Inc. Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

Read More

FUTURE OF HEALTHCARE

Bumrungrad International Hospital, Southeast Asia's Largest Hospital to Deploy Lunit's AI Cancer Screening System

Lunit | July 06, 2022

Lunit, a leading medical AI provider, announced that it has signed a contract with FujiFilm Thailand and Microsoft to supply AI cancer screening products to Bumrungrad International Hospital, located in Bangkok, Thailand. Under the agreement, Lunit INSIGHT CXR, a CE-marked chest x-ray analysis AI software, and Lunit INSIGHT MMG, an FDA-cleared AI solution for detecting breast cancer in early stages, are deployed in Bumrungrad hospital. Lunit and FujiFilm Thailand supply AI solutions to Bumrungrad hospital using Microsoft Azure, a global cloud computing platform. Lunit and Microsoft have been partnering to deliver state-of-the-art medical AI technology to more diagnostic practices globally. Based on previous collaboration experiences, Microsoft Azure will enhance the operation of Lunit's software at Bumrungrad hospital. Bumrungrad, the only Thai hospital named as 'World's Best Hospitals 2022' by Newsweek, is one of the largest private hospitals in Southeast Asia, with 580 beds and treating 1.1 million patients annually from more than 190 different countries. Currently, the hospital is actively using Lunit AI solutions in its check-ups, intensive care units, emergency rooms, and more. Lunit INSIGHT CXR and Lunit INSIGHT MMG analyze more than 100,000 medical images that are annually taken in the hospital. Through AI, Bumrungrad aims to provide better services by timely detection of chest abnormalities and breast cancer. Lunit plans to further support Bumrungrad to drive groundbreaking medical innovation across Southeast Asia. "Bumrungrad International Hospital, widely recognized as an international medical destination, has been creating innovative clinical experiences that can serve patients' needs and solve pain points for nearly four decades. We are delighted to introduce our AI solutions to Bumrungrad, which strives to ensure a healthier life for patients. We also expect the partnership with Microsoft, a leading cloud service provider, will expand the reach of Lunit INSIGHT CXR and Lunit INSIGHT MMG into further sites across the world so that our INSIGHT suite supports more hospitals detecting critical findings." Brandon Suh, CEO of Lunit "Medical imaging has been another area of healthcare identified as 'highly potential' for artificial intelligence (AI) applications. AI would be a support tool for human decision-making, providing a second opinion for doctors' consideration during the diagnostic process. An additional benefit we anticipate for the AI system is its ability to speed up the learning curve for junior doctors with less experience in reading images," said Dr. Teeradache Viangteeravat, Director of Research and Development at Bumrungrad International Hospital. "Lunit is a world leader in this space and can provide a suite of integrated AI solutions, which support our strategic objectives. We are proud to be working with Lunit to implement world-class medical AI imaging solutions to continue delivering high-quality support that fits our patients' and clinicians' demands."

Read More